Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 791 across all filing types
Latest filing 2023-03-27 Report Publication Anno…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Nanobiotix reporte la publication de ses résultats financiers de l'exercice 2022 et la confé?rence téléphonique
Report Publication Announcement Classification · 99% confidence The document is a press release (COMMUNIQUÉ DE PRESSE) dated March 27, 2023, announcing the postponement of the publication of the full-year 2022 financial results and the associated conference call. It explicitly states that a new date will be announced in a future press release. This action—announcing the timing or delay of a report's release—fits the definition of a Report Publication Announcement (RPA). Although it concerns annual results (which would normally be 10-K or ER/MDA), the document itself is merely an announcement about the schedule, not the results or the full report, satisfying the 'MENU VS MEAL' rule.
2023-03-27 French
Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
Report Publication Announcement Classification · 99% confidence The document is explicitly titled "PRESS RELEASE" and announces the postponement of the release of the "full year 2022 financial results and conference call." This is not the financial report itself (10-K or ER), nor is it a transcript (CT) or a formal regulatory filing like a 10-K. It is an announcement about the timing of a future report release. This fits best under Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports. Given the context of postponing an earnings-related event, RPA is the most precise fit among the options provided.
2023-03-27 English
Nanobiotix publiera le 28 mars 2023 ses résultats financiers de l'exercice 2022 et fera le point sur ses activités opérationnelles
Report Publication Announcement Classification · 99% confidence The document is a press release dated March 14, 2023, announcing that NANOBIOTIX will publish its full-year 2022 financial results on March 28, 2023, followed by a conference call on March 29, 2023. This document itself is not the full financial report (10-K or IR), nor is it the detailed management discussion (MDA) or the earnings release (ER) containing the actual figures. Instead, it is an announcement about the *timing* and *release* of future financial reports and related events (conference call details). According to the definitions, the 'Report Publication Announcement' (RPA) category is appropriate for announcements regarding the timing or release of company reports. The document length (6637 chars) is substantial, but its primary function is to schedule the release of the actual results, fitting the RPA description better than ER (which usually contains the results themselves).
2023-03-14 French
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
Report Publication Announcement Classification · 99% confidence The document is a press release announcing the date for the release of the full-year 2022 financial results and an operational update (March 28, 2023), followed by a conference call (March 29, 2023). This structure—announcing *when* results will be released and scheduling a call—is characteristic of an Earnings Release (ER) or a precursor announcement. However, since the document itself is not the actual financial results (which would likely be an ER or IR), but rather an announcement about the *timing* of the results and the subsequent call, it fits best under the category of announcing the release of financial information. Given the options, 'Earnings Release' (ER) is the most appropriate classification for an announcement detailing the date of the full-year financial results release, even if the actual results are not present. It is not a Call Transcript (CT) because it only announces the call, and it is not a Report Publication Announcement (RPA) because it specifically names the financial results being released, making ER more precise than the general RPA.
2023-03-14 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
Share Issue/Capital Change Classification · 95% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (L.233-8 II du Code de commerce and 223-16 du Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of January 31, 2023. This type of mandatory periodic disclosure regarding the total share capital and voting rights structure is a specific regulatory filing requirement, often falling under general regulatory announcements or specific share/capital change notifications. Since it is a mandatory monthly disclosure of the total share capital structure, it most closely aligns with a notification about share capital changes or a general regulatory filing. Given the options, 'Share Issue/Capital Change' (SHA) covers capital structure changes, but this is a routine monthly disclosure of the *total* count, not an issuance event. 'Major Shareholding Notification' (MRQ) deals with ownership thresholds crossing. The most appropriate general category for routine, mandatory regulatory updates not covered by specific financial reports (like 10-K or ER) is 'Regulatory Filings' (RNS), or potentially 'Share Issue/Capital Change' (SHA) if interpreted broadly as a capital structure update. However, since it is a routine monthly update on the total number of shares/votes, it is a specific type of regulatory disclosure. In many databases, these monthly voting rights reports are classified separately or under general regulatory announcements. Given the options, and noting that it is a formal regulatory communication detailing the capital structure, RNS (Regulatory Filings) is the safest fallback, although SHA is also plausible. Let's re-evaluate the definitions. SHA is for 'new share issues, stock splits, or other capital changes.' This is a report *of* the current state, not necessarily a change announcement, although it implies the state changed since the last report. RNS is the general fallback. Since the document is a formal, mandated regulatory communication (Communiqué de Presse) providing specific data required by the AMF, RNS is the best fit as a general regulatory filing type that isn't a full financial report or a specific transaction announcement.
2023-02-14 French
Voting Rights and Shares Capital of the Company
Share Issue/Capital Change Classification · 95% confidence The document is titled "VOTING RIGHTS AND SHARES CAPITAL OF THE COMPANY" and explicitly references French Commercial Code articles (L.233-8 II) and the French Financial Markets Authority (AMF) regulations regarding the disclosure of the total number of voting rights and shares outstanding. It provides a table detailing the number of shares and voting rights as of January 31, 2023. This type of mandatory periodic disclosure concerning the capital structure and voting rights aligns most closely with regulatory reporting requirements that affect shareholder structure, but it is not a standard SEC filing like 10-K or a general earnings release. Since it is a specific regulatory disclosure about the composition of capital and voting power, it fits best under the general 'Regulatory Filings' (RNS) category as a specific, non-standard announcement, or potentially under 'Major Shareholding Notification' (MRQ) if it were about a change in ownership thresholds, but here it is a routine capital update. Given the options, RNS is the most appropriate fallback for specific, non-standard regulatory updates not covered by other codes. It is not a DEF 14A (Remuneration), DVA (Voting Results), or SHA (Share Issue).
2023-02-14 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.